Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that ...

VHH antibodies, they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But ...

The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug ...